Skip to content
Disclosery

Vida Ventures Advisors, LLC

Follow

13F filer, CIK 1831423, BOSTON, MA

Vida Ventures Advisors, LLC reported $180,005,410 across 5 holdings for the quarter ended 2024-03-31, in a 13F-HR filed 2024-04-12.

Filed (acceptance time not in the bulk data set), ingested 13F-HR 0000950123-24-003271

Period
2024-03-31
Reported value
$180M
Holdings
5
Top 10 weight
100%
New
1
Sold out
3

Largest buys vs the previous quarter

SecurityShares changeApprox. value
KYTXnew+4,523,924$112M

Ranked by the share change valued at this quarter's implied price (value over shares in the 13F). A position sold out is valued at the previous quarter's price, its last report.

Largest sells vs the previous quarter

SecurityShares changeApprox. value
DYNreduced-1,667,288-$47.3M
LIANBIO ADRexited-2,282,084-$10.2M
KINNATE BIOPHARMA INCexited-2,207,772-$5.23M
IKENA ONCOLOGY INCexited-225,192-$444K

Ranked by the share change valued at this quarter's implied price (value over shares in the 13F). A position sold out is valued at the previous quarter's price, its last report.

Holdings, Q1 2024

Share positions as resolved from 13F-HR 0000950123-24-003271, largest first. % of portfolio is the value over $180,005,410, the sum of the share positions whose value is usable for ratios (method).

SecurityHistorySharesValue% of portfolioChangeLatest eventTimeline
KYTXKYVERNA THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2022Q2: restricted; 2022Q3: restricted; 2022Q4: restricted; 2023Q1: restricted; 2023Q2: restricted; 2023Q3: restricted; 2023Q4: not reported; 2024Q1: 4,523,924 shares 4,523,924$112M62.43%newTimeline
CNTACENTESSA PHARMACEUTICALS PLCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2022Q2: restricted; 2022Q3: restricted; 2022Q4: restricted; 2023Q1: restricted; 2023Q2: restricted; 2023Q3: restricted; 2023Q4: 3,931,818 shares; 2024Q1: 3,931,818 shares 3,931,818$44.4M24.68%0Timeline
DYNDYNE THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2022Q2: restricted; 2022Q3: restricted; 2022Q4: restricted; 2023Q1: restricted; 2023Q2: restricted; 2023Q3: restricted; 2023Q4: 2,074,787 shares; 2024Q1: 407,499 shares 407,499$11.6M6.43%-1,667,288Timeline
ALLOALLOGENE THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2022Q2: restricted; 2022Q3: restricted; 2022Q4: restricted; 2023Q1: restricted; 2023Q2: restricted; 2023Q3: restricted; 2023Q4: 1,798,163 shares; 2024Q1: 1,798,163 shares 1,798,163$8.04M4.47%0Timeline
KRONOS BIO INCKRONOS BIO INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2022Q2: restricted; 2022Q3: restricted; 2022Q4: restricted; 2023Q1: restricted; 2023Q2: restricted; 2023Q3: restricted; 2023Q4: 2,765,314 shares; 2024Q1: 2,765,314 shares 2,765,314$3.59M2%0

Sold out in Q1 2024

Positions in the previous quarter's report that this quarter's report no longer lists.

SecurityShares beforeValue beforeType
LIANBIO ADRLIANBIO ADR2,282,084$10.2Mshares
KINNATE BIOPHARMA INCKINNATE BIOPHARMA INC2,207,772$5.23Mshares
IKENA ONCOLOGY INCIKENA ONCOLOGY INC225,192$444Kshares

How Q1 2024 was built

Available 13F filings of this filer for the quarter and their roles: the base report is the latest original or restatement, NEW HOLDINGS amendments filed after it are added (method).

FilingRoleAmendmentFiledAcceptedIngested
13F-HR 0000950123-24-003271 base2024-04-12acceptance time not in the bulk data set